We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
-$417M
(-14%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-6.89%
Top 10 Holdings %
Top 10 Hldgs %
30.75%
Holding
151
New
30
Increased
31
Reduced
32
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$42M |
| 2 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$38M |
| 3 |
AAC
AAC Holdings
AAC
|
+$37.8M |
| 4 |
GSK
GSK
|
+$37.7M |
| 5 |
Regenxbio
RGNX
|
+$34.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$132M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$38M |
| 3 |
Inogen
INGN
|
+$26.8M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$25.4M |
| 5 |
Boston Scientific
BSX
|
+$24.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.89% |
| 2 | Financials | 4.77% |
| 3 | Technology | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Axogen
AXGN
$2.12B
| $13.9M | 0.54% |
3,381,439
-345,000
| -9% | -$1.38M |
|
52
Edwards Lifesciences
EW
$49.4B
| $13.8M | 0.53% |
582,714
-688,386
| -54% | -$16.6M |
|
|
ZLTQ
53
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $13.5M | 0.52% |
420,063
-596,390
| -59% | -$19.8M |
|
|
NUVA
54
DELISTED
NuVasive, Inc.
NUVA
| $12.8M | 0.49% |
265,272
-185,000
| -41% | -$9.56M |
|
55
Brookdale Senior Living
BKD
$3.58B
| $12.8M | 0.49% |
+557,000
| New | +$16.4M |
|
56
Orthofix Medical
OFIX
$468M
| $12.2M | 0.47% |
360,459
-97,240
| -21% | -$3.46M |
|
|
XNPT
57
DELISTED
XENOPORT, INC.
XNPT
| $12M | 0.46% |
+3,445,374
| New | +$21.7M |
|
58
MacroGenics
MGNX
$285M
| $11.9M | 0.46% |
+557,000
| New | +$17.5M |
|
59
Trupanion
TRUP
$1.16B
| $11.9M | 0.46% |
1,578,925
-136,286
| -8% | -$1.08M |
|
|
EPIX
60
DELISTED
ESSA Pharma
EPIX
| $11.6M | 0.45% |
+92,964
| New | +$13M |
|
|
ACHN
61
DELISTED
Achillion Pharmaceuticals
ACHN
| $11.5M | 0.45% |
+1,667,000
| New | +$13.6M |
|
|
ALIM
62
DELISTED
Alimera Sciences
ALIM
| $9.77M | 0.38% |
294,705
| – | – |
|
|
NEOS
63
DELISTED
Neos Therapeutics, Inc
NEOS
| $9.63M | 0.37% |
+458,332
| New | +$10.1M |
|
|
GEN
64
DELISTED
Genesis Healthcare, Inc.
GEN
| $9.43M | 0.36% |
1,538,232
-581,384
| -27% | -$3.94M |
|
|
ARNA
65
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.86M | 0.34% |
464,088
-234,283
| -34% | -$7.96M |
|
66
Pacific Biosciences
PACB
$447M
| $8M | 0.31% |
2,185,771
+699,910
| +47% | +$3.42M |
|
67
Novavax
NVAX
$1.35B
| $7.35M | 0.28% |
+52,000
| New | +$11.7M |
|
|
HTWR
68
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $7.02M | 0.27% |
+134,200
| New | +$10.2M |
|
|
OXFD
69
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $7.02M | 0.27% |
519,670
-41,556
| -7% | -$563K |
|
70
Tonix Pharmaceuticals
TNXP
$198M
| – | – |
0
| – | – |
|
|
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $6.96M | 0.27% |
948,934
| – | – |
|
|
EGLT
72
DELISTED
Egalet Corporation
EGLT
| $6.29M | 0.24% |
+477,123
| New | +$6.06M |
|
|
SIOX
73
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $6.26M | 0.24% |
+60,583
| New | +$7.1M |
|
74
Arcturus Therapeutics
ARCT
$172M
| $6.02M | 0.23% |
142,478
-13,015
| -8% | -$685K |
|
75
Rigel Pharmaceuticals
RIGL
$750M
| $5.92M | 0.23% |
239,786
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2015 Portfolio in Review
As of Q3 2015, Deerfield Management held 151 positions worth $2.59B, down 14% from $3B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Deerfield Management withdrew a net $178M in Q3 2015, closing 17 positions and reducing 32 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Global Blood Therapeutics, Inc. worth $37.5M.
- Deerfield Management's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 890,620 shares worth $37.5M.
- Deerfield Management added most to AAC Holdings in Q3 2015, an estimated $37.8M increase.
- Deerfield Management's biggest Q3 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $132M.
- Deerfield Management fully exited Spark Therapeutics, Inc. Common Stock in Q3 2015, selling an estimated $38M.
- Deerfield Management's ten largest holdings make up 31% of its $2.59B portfolio in Q3 2015.
- Deerfield Management opened 30 new positions and closed 17 in Q3 2015.
- Deerfield Management's portfolio value fell 14% quarter-over-quarter to $2.59B.
Based on Deerfield Management's 13F filing for Q3 2015, filed 16 Nov 2015.